11 / 39
Supervivencia Global
Motzer et al.
N Engl J Med
. 2015;373(19):1803-1813
.
Median OS,
months
(95% CI)
Nivolumab
25.0 (21.8–NE)
Everolimus
19.6 (17.6–23.1)
0
3
6
12
9
15
Months
18
21
24
27
30
33
# of patients at risk
Nivolumab
410
389
359
337
305
275
213
139
73
29
3
0
411
366
324
287
265
241
187
115
61
20
2
0
Everolimus
0.0
0.3
0.1
0.2
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Overall Survival (Probability)
Nivolumab
Everolimus
HR 0.73 (98.5% CI, 0.57 to 0.93; p 0.002)
Data cut-off (june 2015), minimum follow-up 14 months